Don’t invest unless you’re prepared to lose all your money. These are high-risk investments and you are unlikely to be protected if something goes wrong.

Aquarate is preventing hydration-related illness through sensor based technology and products.

aquarate nurse and patient


Rebecca Taylor


Digital Health


aquarate logo

Startup opportunity

Poor fluid balance monitoring (the control of water levels within the body) is a problem that costs the NHS and private care facilities over a billion pounds per year within the UK. The current system is reliant on nurses verbally asking patients how much they’ve had to drink, or guesstimating this based on water displacement. Unsurprisingly this is highly inaccurate, time-consuming and has detrimental effects on patient care.

Aquarate founder Rebecca Taylor came to Nova having extensively researched this area for her final year University project. She knew that there was a better way to do this, and believed the solution could be achieved through sensor-based technology.

aquarate cups

Since our investment and working with Nova

  • Validated concepts, designs and prototypes through industry user groups
  • Design and production of tech hardware – Mug, Cup and Charging Tray
  • Developed web app monitoring software for patients and carers
  • Creation of brand, website & go to market strategy
  • Secured trials in major UK hospital and care facilities
  • Submitted patent and IP protection applications

Inside our portfolio businesses – Aquarate


“Startups can be a lonely venture, but with Nova as my co-founder I’ve had a passionate team engaging with me throughout the process. I’ve been able to take an idea surrounding a known problem and follow it through to a tested and validated solution”

Rebecca Taylor, founder of Aquarate

Up next

Hy-genie is innovative hand hygiene improving patient safety and reducing healthcare associated infections.

awards 2021
Please read our full risk warning and disclaimer:

Investments of this nature carry risks to your capital. The risks include illiquidity where shares may not be able to be sold easily, lack of dividends and dilution. Past performance is not indicative of future returns. Investors should only invest a proportion of their available investment funds into Nova Cofoundery SEIS & EIS Fund as these investments are high risk.

The availability of any tax relief, including EIS and SEIS, depends on the individual circumstances of each investor and of the company concerned, is only available for UK investors in qualifying companies and may be subject to change in the future. If you are in any doubt about the availability of any tax reliefs, or the tax treatment of your investment, you should obtain independent tax advice before proceeding with your investment.

Nova Growth Capital Limited is a private limited company registered in England and Wales (Company Number 11591402). Nova Growth Capital Limited (FRN 826519) is an Appointed Representative of Sapphire Capital Partners LLP (FRN 565716), who are authorised and regulated by the Financial Conduct Authority.

NGC white logo
facebook icon
twitter icon
linkedin icon
youtube icon
NGC Footer Logo

5% initial fees and 2% annual fees paid by the Fund Investee Companies, resulting in 100% allocation of investment for tax reliefs with no additional fees. 20% performance fee only once on original investments that return over 150%.

Registered address: Nova Growth Capital, 57 Jordan Street, Liverpool, Merseyside, England, L1 0BW